The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic ... strategic moves like Vertex's 2024 partnership with Zai Lab Limited expanded its presence in Asia, enhancing its global ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Jim Lebenthal names Vertex Pharmaceuticals as his final trade. Joshua Brown says Netflix is close to its 52-week high. Markets are swinging wildly, but for Matt Maley, it's just another ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.